Abliva

Abliva is a Lund-based pharmaceutical company developing therapies targeting mitochondrial dysfunction, with a focus on acute kidney injury (AKI). Its lead candidate KL1333 is being developed in collaboration with Yungjin Pharm (South Korea) and addresses conditions where mitochondrial function is impaired. Listed on Nasdaq First North, Abliva has approximately 10–15 employees and is headquartered at Medicon Village in Lund.